Search Medical Condition
Please enter condition
Please choose location from dropdown

Kanagawa, Yokohama, Japan Clinical Trials

A listing of Kanagawa, Yokohama, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (226) clinical trials

A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)

The primary objective of this study is to evaluate the number of adverse events (AEs)and discontinuation due to AEs through up to 52 weeks of treatment with gefapixant in Japanese adult participants with refractory or unexplained chronic cough.

Phase

0.0 miles

Learn More »

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)

Study consists of an open-label, safety run-in part and a randomized, double-blind, placebo-controlled Phase 2/3 part. In the Phase 2/3 part, the study will evaluate whether bintrafusp alfa in combination with the current standard of care (SoC) (gemcitabine plus cisplatin) improves overall survival (OS) or progression-free survival (PFS) in chemotherapy ...

Phase

0.0 miles

Learn More »

SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

The expected duration of study intervention for participants who benefit from study intervention may vary, based on progression date; but median expected duration of study per participant is estimated as median 9 months in docetaxel arm (1 month for screening, 4 months for treatment, and 4 months for the end ...

Phase

0.0 miles

Learn More »

Phase 2 Study of SAR439859 Versus Physician's Choice in Premenopausal and Postmenopausal Locally Advanced or Metastatic ER-positive Breast Cancer

The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (28 days of study treatment), and an end of treatment (EOT) visit at least 30 days (or ...

Phase

0.0 miles

Learn More »

Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

Study design: Prospective multi-center non-interventional cohort study Data Source(s): Medical records of patients who are treated with durvalumab following chemoradiation therapy Study Population: Patients prescribed and treated with durvalumab for unresectable stage III non-small cell lung cancer (NSCLC) at first time following chemoradiation therapy and who provide written informed consent. ...

Phase N/A

0.0 miles

Learn More »

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).

Phase

0.0 miles

Learn More »

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

This is a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell malignancies. This study intends to assess the use of zanubrutinib as an investigational agent to develop new treatment options for Japanese participants with B-cell malignancies. No formal hypothesis testing will be performed given the small sample ...

Phase

0.0 miles

Learn More »

Lynparza Breast Cancer Clinical Experience Investigation

To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.

Phase N/A

0.36 miles

Learn More »

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo

Phase

0.36 miles

Learn More »